Successful and Safe Use Of Icatibant For Life-Threatening Angioedema Attack During Pregnancy In a Patient With Hereditary Angioedema Type I

Boufleur, Karine; Delcaro, Luana; Cordeiro, Daniel; Palhas, Priscila; Sousa, Janaina Fernandes de Melo; Mendonça, Thaís; Melo, Janaina Michele de Lima; Neppelenbroek, Gustavo A.; Sarti, Willy; Moreno, Adriana S.; Arruda, L. Karla

doi:10.1016/j.jaci.2013.12.153

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 A concern for the use of icatibant during pregnancy is that cells of the human decidua express bradykinin B2 receptors, and the effects of inhibition on these receptors, even for transient periods, are unknown. 11,12 Cases of short-term use of icatibant during pregnancy have been documented [13][14][15] but with limited use compared with our patient in this report.…”

mentioning

confidence: 61%

“…In the abstract, a 40-year-old woman with type 1 HAE had an upper airway attack treated with icatibant at both 32 and 35 weeks of pregnancy. 15 At week 36 of pregnancy, she treated abdominal pain with icatibant before the pain was recognized as labor, and she underwent an uncomplicated Caesarian section 6 hours later. She gave birth to a healthy infant.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Multiple Doses of Icatibant used during Pregnancy

Kaminsky

Kelbel

Ansary

et al. 2017

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

Background:Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are not approved for use during pregnancy.Objective:We report the outcomes of three pregnancies during which icatibant was used by a patient with HAE with normal C1-inhibitor for treatment of attacks. We also reviewed the literature for reports of icatibant use during pregnancy for outcomes and adverse events.Methods:We report on a patient who treated herself with icatibant during three separate pregnancies. Postpartum follow-up verified the health of the mother and children. We also performed a complete literature search of medical literature data bases on icatibant use during pregnancy.Results:The patient in our report administered multiple doses of icatibant during three pregnancies. The child born from the first pregnancy and the child from the third pregnancy were born at term and without congenital anomalies. The child from the second pregnancy was 1-month preterm. All three children were developmentally normal. The literature search identified two case reports and one abstract of limited icatibant use without adverse events during pregnancy in patients with HAE. These pregnancies resulted in the births of healthy infants.Conclusion:From a search of the literature, three cases of icatibant use during pregnancy resulted in healthy infants. In addition, we report that from icatibant use in three separate pregnancies, one infant was born prematurely, but there were no birth defects. From follow-up, the children continued meeting developmental milestones. This report adds to the acquisition of knowledge for drug adverse events during postmarketing surveillance for icatibant use during pregnancy.

show abstract

mentioning

confidence: 61%

Section: Resultsmentioning

confidence: 99%